Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections

Background Immune checkpoint inhibitors (ICI) substantially improve outcome for patients with cancer. However, the majority of patients develops immune-related adverse events (irAEs), which can be persistent and significantly reduce quality of life. Neurological irAEs occur in 1–5% of patients and c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2023-11, Vol.72 (11), p.3475-3489
Hauptverfasser:	Schmitt, C., Hoefsmit, E. P., Fangmeier, T., Kramer, N., Kabakci, C., Vera González, J., Versluis, J. M., Compter, A., Harrer, T., Mijočević, H., Schubert, S., Hundsberger, T., Menzies, A. M., Scolyer, R. A., Long, G. V., French, L. E., Blank, C. U., Heinzerling, L. M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Bacteria Cancer Research Clinical trials Complications Cytomegalovirus Hepatitis A Herpes simplex Herpes viruses Immune checkpoint inhibitors Immunology Infections Influenza A Medicine Medicine & Public Health Melanoma Neurotoxicity Oncology Parvoviruses Pseudotuberculosis Quality of life Risk factors Serology Varicella Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!